189 related articles for article (PubMed ID: 31838166)
1. Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival.
McGonagle D; Bragazzi NL; Amital H; Watad A
Autoimmun Rev; 2020 Feb; 19(2):102456. PubMed ID: 31838166
[TBL] [Abstract][Full Text] [Related]
2. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells.
Alissafi T; Hatzioannou A; Legaki AI; Varveri A; Verginis P
J Autoimmun; 2019 Nov; 104():102310. PubMed ID: 31421963
[TBL] [Abstract][Full Text] [Related]
3. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
Berner F; Flatz L
Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043
[TBL] [Abstract][Full Text] [Related]
4. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.
Khan S; Gerber DE
Semin Cancer Biol; 2020 Aug; 64():93-101. PubMed ID: 31330185
[TBL] [Abstract][Full Text] [Related]
5. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT; Sharma P; Davis SL; Jimeno A
Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy.
Ohnuma K; Hatano R; Dang NH; Morimoto C
Mod Rheumatol; 2019 Sep; 29(5):721-732. PubMed ID: 30285531
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity.
Singh N; Hocking AM; Buckner JH
Immunol Rev; 2023 Sep; 318(1):81-88. PubMed ID: 37493210
[TBL] [Abstract][Full Text] [Related]
9. Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life.
Schulz TU; Zierold S; Sachse MM; Pesch G; Tomsitz D; Schilbach K; Kähler KC; French LE; Heinzerling L
Eur J Cancer; 2022 Nov; 176():88-99. PubMed ID: 36198246
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity.
Boland P; Pavlick AC; Weber J; Sandigursky S
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303614
[TBL] [Abstract][Full Text] [Related]
11. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
13. [The pathology of adverse events with immune checkpoint inhibitors].
Koelzer VH; Glatz K; Bubendorf L; Weber A; Gaspert A; Cathomas G; Lugli A; Zippelius A; Kempf W; Mertz KD
Pathologe; 2017 May; 38(3):197-208. PubMed ID: 28421272
[TBL] [Abstract][Full Text] [Related]
14. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy.
Ho AK; Ho AM; Cooksley T; Nguyen G; Erb J; Mizubuti GB
Anesth Analg; 2021 Feb; 132(2):374-383. PubMed ID: 33009134
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint Inhibitors: Applications for Autoimmunity.
Tocheva AS; Mor A
Curr Allergy Asthma Rep; 2017 Sep; 17(10):72. PubMed ID: 28956259
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.
Kim ST; Tayar J; Trinh VA; Suarez-Almazor M; Garcia S; Hwu P; Johnson DH; Uemura M; Diab A
Ann Rheum Dis; 2017 Dec; 76(12):2061-2064. PubMed ID: 28830882
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for immune-related adverse events associated with immune checkpoint inhibitors.
Chen YH; Kovács T; Ferdinandy P; Varga ZV
Br J Pharmacol; 2024 May; ():. PubMed ID: 38803135
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity.
Thanarajasingam U; Abdel-Wahab N
Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606
[TBL] [Abstract][Full Text] [Related]
19. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
[TBL] [Abstract][Full Text] [Related]
20. Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity.
Shatila M; Ma W; Cui Y; Naz S; S Thomas A; N De Toni E; Török HP; Khaled NB; Altan M; Schneider B; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7793-7803. PubMed ID: 37029815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
